Abstract Introns are found in all eukaryotes and are one of the defining characteristics of eukaryotes. After transcription, pre-mRNAs undergo splicing, and introns are excised in the lariat structure. Since excised introns are degraded quickly after debranching, they have been considered as byproducts of gene expression, and their post-splicing role in the cells remains unclear. Here, we find that the inhibition of intron debranching process by depleting a debranching enzyme, DBR1, results in hyperactivation of protein kinase R (PKR) due to accumulation of intron lariat-derived transposable elements (TEs) that can adopt double-stranded secondary structure. Through in vitro PKR-binding assay, we show that PKR strongly binds to intron lariat RNAs harboring TEs, especially inverted Alu repeats. Interestingly, these TE-containing lariat RNAs are retained in the nucleus, but are released to the cytosol during mitosis, where they activate PKR, resulting in aberrant mitotic progression and apoptosis. We further exploit the lariat RNA-PKR interaction during mitosis and show that DBR1 depletion and anti-mitotic chemotherapy drugs can synergistically induce cancer cell death both in vitro and in vivo. Lastly, we perform docking simulation-based screening of DBR1-inhibitory small molecules. Collectively, our findings underscore the significance of intron turnover in avoiding innate immune activation and further suggest a potential strategy to enhance the efficacy of anti-mitotic drugs by targeting intron processing. Citation Format: Keonyong Lee, Jayoung Ku, Tria Asri Widowati, Namwook Kim, Soo Young Park, Han Suk Ryu,Yoosik Kim. Exploiting the immunoregulatory effect of double-stranded RNAs for cancer therapeutics [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer; 2024 Nov 14-17; Bellevue, Washington. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(11_Suppl):Abstract nr I005.
Read full abstract